These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33585159)

  • 21. Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
    Zenone MA; Snyder J; Crooks V
    BMC Public Health; 2021 Jul; 21(1):1285. PubMed ID: 34210299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
    Newton M; Newton DW
    J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
    [No Abstract]   [Full Text] [Related]  

  • 23. Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products.
    Tran T; Kavuluru R
    Int J Drug Policy; 2020 Mar; 77():102688. PubMed ID: 32092666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
    Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
    Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
    [No Abstract]   [Full Text] [Related]  

  • 25. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
    Miller OS; Elder EJ; Jones KJ; Gidal BE
    Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
    Crippa JA; Guimarães FS; Campos AC; Zuardi AW
    Front Immunol; 2018; 9():2009. PubMed ID: 30298064
    [No Abstract]   [Full Text] [Related]  

  • 28. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review: Cannabinoids as Medicinals.
    Khalsa JH; Bunt G; Blum K; Maggirwar SB; Galanter M; Potenza MN
    Curr Addict Rep; 2022; 9(4):630-646. PubMed ID: 36093358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence.
    Arnold JC; McCartney D; Suraev A; McGregor IS
    Clin Transl Sci; 2023 Jan; 16(1):10-30. PubMed ID: 36259271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabidiol - therapeutic and legal aspects.
    Vlad RA; Hancu G; Ciurba A; Antonoaea P; Rédai EM; Todoran N; Silasi O; Muntean DL
    Pharmazie; 2020 Oct; 75(10):463-469. PubMed ID: 33305718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
    Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabinoid Content and Label Accuracy of Various Hemp-Derived Haircare, Cosmetic, and Edible Products Available at Retail Stores and Online in the United States.
    Dowd AN; Zamarripa CA; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; ElSohly K; Gul W; Shahzadi I; Mullen LD; Winecker RE; Flegel RR; Vandrey R; Spindle TR
    Cannabis Cannabinoid Res; 2024 Jul; ():. PubMed ID: 39029473
    [No Abstract]   [Full Text] [Related]  

  • 35. Current Cannabidiol Safety: A Review.
    Singh C; Rao K; Yadav N; Vashist Y; Chugh P; Bansal N; Minocha N
    Curr Drug Saf; 2023; 18(4):465-473. PubMed ID: 36056846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim.
    Johnson E; Kilgore M; Babalonis S
    J Cannabis Res; 2022 Jun; 4(1):28. PubMed ID: 35658956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic role of Cannabidiol in mental health: a systematic review.
    Khan R; Naveed S; Mian N; Fida A; Raafey MA; Aedma KK
    J Cannabis Res; 2020 Jan; 2(1):2. PubMed ID: 33526132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current legal status of medical marijuana and cannabidiol in the United States.
    Alharbi YN
    Epilepsy Behav; 2020 Nov; 112():107452. PubMed ID: 32956945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.